Oncology Vol 30 No 3

Our commentary aims to expand on the evolution and present state of the art in the pathology of HPV in penile cancer and precancerous lesions.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common treatment-related side effect of several widely used drugs. Agents known to cause CIPN include platinum analogs, antitubulins, proteasome inhibitors, immunomodulatory agents, and some of the newer biologics.

The promise of vaccine-based anticancer therapies has been explored for a number of years. However, the research met with little success in its early phases, largely because of a poor understanding of the biology of the immune system and its role in combatting cancer.

Lung cancer exhibits a wide spectrum of behavior, from inconsequential to nonaggressive, typically aggressive, and very aggressive lung cancer. The proportion of “well-behaved” cancers has clearly been increased by the advent of CT screening.

The mandate of the National Cancer Act of 1971 was “to support research and the application of the results of research, to reduce the incidence, morbidity, and mortality from cancer,” and we have done that.

Over the past 5 years, several studies have investigated the molecular profiling of penile carcinomas, examining both genomic and epigenetic alterations. These studies have revealed distinct molecular pathways associated with HPV status.

We must now come to a uniform consensus regarding the descriptions of these risk groups in order to truly determine which treatments have the best oncologic efficacy, while minimizing overtreatment and optimizing patients’ quality of life.